


Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia

Chun Ling^{1,2}, Nengneng Cao¹, Huiping Wang¹, Yang Wan¹, Xue Liang¹, Jinjing Guo¹, Meng Xiao¹, Qiguo Zhang², Zhimin Zhai¹ 

¹Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230000, People's Republic of China;

²Department of Hematology, Affiliated Chuzhou Hospital of Anhui Medical University, First People's Hospital of Chuzhou, Chuzhou, Anhui, 239001, People's Republic of China

Correspondence: Zhimin Zhai, Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230000, People's Republic of China, Email zzzm886@163.com

Background: Acute Myeloid Leukemia (AML) is a prevalent neoplastic disorder. The roles of E3 ubiquitin ligases and related genes in AML drug resistance and prognosis remain unclear.

Methods: Genes were identified from GeneCards and UniProt databases, differentially expressed genes were selected based on transcriptional sequencing data from wild-type and Adriamycin-resistant HL60 (HL60/WT & HL60/ADR) cell lines, and the intersection of these three sources was taken. We then constructed a prognostic model comprising five genes (HBP1, RNF130, RMND5B, TRIM32, and UBE2L3) through univariate Cox and LASSO regression analyses in the TCGA cohort and validated it in the BeatAML2.0 cohort. Finally, the expression of UBE2L3 was verified in cell lines and clinical case specimens.

Results: The model accurately predicted AML prognosis and identified the UBE2L3 gene within the model as a high-risk biomarker associated with drug resistance, significantly influencing AML outcomes.

Conclusion: The high expression of UBE2L3 is a reliable biomarker for drug resistance and poor prognosis of acute myeloid leukemia.

Keywords: E3 ubiquitin ligase, prognostic model, UBE2L3, acute myeloid leukemia, drug resistance

Introduction

Acute myeloid leukemia is a common and highly heterogeneous malignant disease of the hematologic system. Over the past 30 years, the incidence of AML has seen a global increase, presenting a significant risk to public health due to its poor prognosis.¹ Drug resistance and relapse are important factors affecting the survival of AML patients. With the deepening of research, more and more genetic landscape features of AML have been discovered, and the molecular mechanisms of drug resistance have become clearer.² The ubiquitin-proteasome pathway regulates nearly all cellular activities through protein degradation and non-proteolytic events; it is closely associated with the occurrence and development of cancer and plays a central role in regulating protein levels and controlling crucial cellular processes such as the cell cycle, gene expression, cellular oxidative stress, proliferation, apoptosis, and DNA repair.^{3,4} Thus, this pathway has a major impact on tumorigenesis and other pathology-related events, inhibition of the pathway could represent a novel strategy for the treatment and overcoming of drug resistance in chemoresistant malignancies.⁵

Over 600 E3 ligases have been identified in the human body, but only a few of targeted degron instances have been identified so far.^{6,7} E3 ubiquitin ligases play an important role in the ubiquitin proteasome-pathway, and the E3 ubiquitination step determines the overall specificity of ubiquitination of target proteins, with activated ubiquitin usually

transferred to lysine residues in the substrate. Depending on the structure, E3 ligases mainly include HECT, RING Finger and U-box structural domain E3s, which stimulate the transfer of ubiquitin and ubiquitin-like proteins by direct or indirect mechanisms.⁸ E2 ligases are essential partners of E3 ligases because all E3 ligases bind to E2~Ub thioesters and catalyze the transfer of ubiquitin from E2 to the substrate lysine via an amino lysis reaction, thereby determining each protein final destination.^{9,10} After bortezomib achieved previously unmatched efficacy in the treatment of multiple myeloma, the study of the ubiquitin-proteasome pathway in hematological tumor has received increasing attention.¹¹ Several mechanisms involving E3 ubiquitin ligase-related genes in AML have been gradually uncovered. For example, Cbl-b, by ubiquitinating and promoting the degradation of Siva1, activates the P53 pathway, potentially overcoming FLT3 inhibitor-resistant AML.¹² Triad1 antagonizes Mll-Ell induced AML progression in vivo and can act as an AML suppressor.¹³ WWP1 promotes cell cycle entry and survival of AML progenitors, maintaining leukemia cell growth; its inactivation might promote autophagy and slow disease progression.¹⁴ RNF5 regulates transcription in AML cells, promoting their proliferation, and its inhibition enhances ER stress-induced AML cell apoptosis.¹⁵ UBE2C regulates the PI3K/AKT signaling pathway to affect AML cell survival and may modulate the sensitivity of leukemia cells to ferroptosis.¹⁶ These findings suggest potential new therapeutic targets. Inhibitors of certain ubiquitin ligases have been discovered and have shown relatively good efficacy in clinical applications.¹⁷⁻¹⁹

UBE2L3, as an E2 ubiquitin ligase involved in the ubiquitination of various substrate proteins. Studies have demonstrated that UBE2L3 is aberrantly expressed in cancer cell lines and tumor tissues, indicating its involvement in various cancer-related signaling pathways. Tao NN et al showed that UBE2L3 overexpression in hepatocellular carcinoma promotes apoptosis evasion by inhibiting the GSK3 β /p65 pathway.²⁰ In cervical cancer, UBE2L3 and E6AP promote tumor cell proliferation by degrading p53, which blocks p53-mediated growth arrest and apoptosis.²¹ Another study indicates that the fusion of UBE2L3 with KRAS may facilitate metastatic progression in rare subgroups of prostate cancer.²² UBE2L3 drives tumor initiation, progression, and metastasis by regulating cancer-associated signaling pathways and other proteins not previously discussed.²³ However, its role in hematological malignancies remains unclear.

An increasing number of studies have shown that the ubiquitin-proteasome pathway plays an important role in tumor progression. Currently, there has been no systematic study of E3 ligases in AML, making our research highly significant. Therefore, in-depth study of the role of E3 ligase-related genes in drug resistance and progression of AML, as well as the establishment of relevant prognostic models, are of great significance for the treatment of AML. In addition, we validated the expression of UBE2L3 in K562 and HL60 cell lines and their drug-resistant strains, as well as in clinical samples; finally, we determined that UBE2L3 may be a reliable biomarker of drug resistance and poorer prognosis in AML.

Materials and Methods

Data Acquisition and Preprocessing

RNA-sequencing data were downloaded from The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov>) for the TCGA-LAML project using the STAR workflow. Such data, were extracted in TPM format, data standardization uses $\log_2(\text{value}+1)$. Beat AML 2.0 data from www.vizome.org.² Prior to analysis, data preprocessing steps were performed, including data cleaning, removal of outliers, batch effect correction, and principal component analysis.

Identification of Differentially Expressed E3 Ubiquitin Ligase-Related Genes

The E3 ubiquitin ligase itself and related genes involved in its functional regulation are regarded as E3 ubiquitin ligase-related genes. These genes are from <https://www.genecards.org> and <https://www.uniprot.org>. Transcriptome sequencing was performed on wild-type and Adriamycin-resistant HL60 cells. Significance thresholds of $P < 0.05$ and $|\log_2 \text{fold change (FC)}| > 1.5$ were used as the screening criteria. The results showed that 3209 genes had their expression upregulated and 2509 genes downregulated. A total of 154 E3 ubiquitin ligase-related differentially expressed genes were identified by taking the intersection with the previously searched genes.

Enrichment Analysis of Differentially Expressed Genes

The input list of differentially expressed molecules was converted into IDs using the “org.Hs.eg.db” package, followed by enrichment analysis using the “cluster Profiler” package. The ggplot2 package was used to visualize the results of the enrichment analysis.

Identification of Prognostic Genes

One hundred and seventy-three AML samples were curated from the TCGA database, of which 139 possessed relatively complete clinical data. To investigate the relationship between the expression levels of E3 ubiquitin ligase-related genes and overall survival (OS) of AML patients, we performed univariate Cox regression analysis using the “survival” package. The significance filter criterion was set at $p < 0.05$ for further analysis. Next, we used LASSO Cox regression to eliminate gene collinearity and reduce the number of genes. Finally, we performed multiple Cox regression analysis based on univariate Cox regression.

Construction and Validation of a Prognostic Model Based on Differentially Expressed E3 Ubiquitin Ligase Genes

The risk score was calculated based on AML mRNA expression data from the training set ($n=139$), using the following formula: $Riskscore = \sum_{i=1}^n x_i y_i$. Patients with AML were divided into high- and low-risk groups based on the median risk score, and the OS of the two groups was analysed. To enhance the reliability of the model, validation was performed using the test set ($n=614$) and the risk score was calculated using the aforementioned formula. Patients with AML in the test set were also divided into high- and low-risk groups based on the median risk score, and the OS of the two groups was compared. Subsequently, univariate and multivariate Cox regression analyses were performed to determine whether the risk score was an independent prognostic factor for OS in patients with AML in the training set. The covariates included age, sex, white blood cell count, molecular mutation and cytogenetic risk.

Construction of a Nomogram and Calibration Curves, Decision Curve Analysis, Survival Curves (Kaplan-Meier Plots)

The “RMS” package in R software (R Foundation for Statistical Computing, Vienna, Austria) was used to construct a nomogram to predict individual survival probabilities and to plot calibration curves for predicting 1, 2, and 3-year survival rates of patients with AML. Use the glm function to construct two-category logistic models respectively, and use the “rmda” package to calculate the corresponding net rate of return and visualize it. Proportional hazards hypothesis testing and fitting survival regression were performed using the “survival” package, and the results were visualized using the “survminer” and “ggplot2” packages.

Patient and Ethics Approvals

The criteria for defining newly diagnosed or relapsed/refractory AML in this study were based on the NCCN (National Comprehensive Cancer Network) guidelines. Induction chemotherapy for patients with AML followed the DA/IA (idarubicin, 8–12mg/m²/day, for 3 days or daunorubicin, 45–60mg/m²/day, for 3 days; and cytarabine, 100 mg/m²/day, for 7 days) regimen, Consolidation chemotherapy for patients with AML followed the medium-dose cytarabine (cytarabine, 2.0g/m²/q12h, for 3 days), and the assessment of treatment efficacy was also based on the NCCN guidelines. We gathered data from 49 AML patients with a follow-up duration of at least 6 months, 8 of whom relapsed. During the follow-up period, none of the patients who underwent allogeneic hematopoietic stem cell transplantation experienced relapse. This study was approved by the Ethics Committee of Affiliated Chuzhou Hospital of Anhui Medical University, First People’s Hospital of Chuzhou and all procedures were performed in accordance with the ethical guidelines of the Declaration of Helsinki. Informed consent was obtained from each participant before their participation in the study.

Leukemia Cell Line Culture

K562 and HL60 cell lines were obtained from the Hematology Laboratory of the Second Affiliated Hospital of the Anhui Medical University. The K562/Adriamycin-resistant (ADR) and HL60/Adriamycin-resistant (ADR) cell lines were generously provided by Professor Li Zhao from the Center Laboratory of the First Hospital of Lanzhou University.²⁴ The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2.05 mm L-glutamine. All cells were cultured in a humidified incubator at 37 °C with 5% CO₂.

Real-Time PCR and Western Blotting

Total RNA was extracted using the TRIzol method and the total RNA was reverse transcribed using the HI Script III RT Super Mix for qPCR (+gDNA) kit (Vazyme Biotech, #R323-01). Real-time PCR was performed using the Roche Light Cycler 480 II PCR amplification system with a mixture of cDNA, gene-specific primers, and 2× ChamQ Universal SYBR qPCR Master Mix (#Q711-02; Vazyme Biotech). The primer sequences used were as follows: UBE2L3: F-CGCTGGCGGGCAAAGACT; R-GCCCCTTTTCGTGCGATGTTTG. β-actin: F: TGGCACCCAGCACAATGAA; R: CTAAGTCATAGTCCGCCTAGAAGCA. Cells were lysed in RIPA buffer, and proteins were extracted and denatured. Proteins were then separated by SDS-PAGE gel electrophoresis and transferred onto nitrocellulose membranes. After blocking with skim milk, the membranes were incubated overnight with specific primary antibodies (Proteintech, #14415-1-AP, #66009-1-Ig) followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 1 hour. Finally, an enhanced chemiluminescence system (Tanon, China) was used for visualization.

Statistical Analysis

SPSS software version 21.0 (SPSS Inc, Chicago, IL, United States) and R software version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria) were used to analyse the data. Statistical significance was set at a two-sided $P < 0.05$.

Results

Identification of Differentially Expressed E3 Ubiquitin Ligase-Related Genes in AML

Our detailed workflow is shown in (Figure 1). To identify the key differentially expressed genes associated with drug resistance in AML, transcriptome sequencing to evaluate the gene expression profiles of wild-type HL60 cells (HL60-WT) and Adriamycin-resistant HL60 cells (HL60/ADR) cells were performed. To identify as many differentially expressed genes as possible, we used a significance criterion with an adjusted p-value < 0.05 , and $|\log_2(\text{fold change})| \geq 1.5$ to evaluate differential gene expression. We identified 3209 upregulated and 2509 downregulated genes (Figure 2A). The intersection of the differential genes from transcriptome sequencing, the E3 ubiquitin ligase-related genes searched in the GeneCards database and the UniProt database (Figure 2B).

Functional Enrichment Analysis

To better understand the functions of differentially expressed E3 ubiquitin ligase-related genes, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. The analysis revealed that the differentially expressed genes associated with E3 ubiquitin ligases were primarily involved in the ubiquitin-proteasome pathway, which was consistent with the screening results (Figure 2C).

Construction of a Prognostic Model Based on E3 Ubiquitin Ligase-Related Genes in the Train Set

As shown in (Figure 2D), we screened out 25 E3 ubiquitin ligase-related genes with $P < 0.05$ using univariate Cox regression analysis. On the basis of the univariate Cox regression, we then performed LASSO regression analysis (Figure 2E and F). Next, we constructed the prognostic E3 ubiquitin ligase-related model using HBP1, RNF130, RMND5B, TRIM32, and UBE2L3 by LASSO regression. Finally, we performed multivariate Cox regression analysis




Figure 1 The flowchart of our research process. TCGA, The Cancer Genome Atlas database; BeatAML2.0, Beat Acute Myeloid Leukemia 2.0. The UniProt and GeneCards database website can be accessed at uniprot.org. and genecards.org. Transcriptome sequencing data from Shanghai Sanshu Biotechnology Co., Ltd (Shanghai, China).

and identified three E3 ubiquitin ligase-related genes, two of which were potential risk genes and one of which was potential protective genes (Figure 2G). Gene expression heat maps of the model based on transcriptome sequencing, as shown in (Figure 2H).

By establishing the model, a prognostic index for the samples was constructed using the following formula: HBP1 expression level $\times (-0.0355832045)$ + RNF130 expression level $\times (-0.0319662324)$ + RMND5B expression level $\times 0.0546280923$ + TRIM32 expression level $\times 0.0008787761$ + UBE2L3 expression level $\times 0.1736809863$. Based on the median risk score, divide patients in the training set and test set into high-risk and low-risk groups. Compared with the




Figure 2 Construction of a risk prognosis model based on E3 ubiquitin ligase-related genes in the TCGA cohort. **(A)** Volcano plot of the transcriptome sequencing of HL60-WT and HL60/ADR cells. **(B)** Venn diagram showing differential genes screened from GeneCards data, UniProt database, and sequencing data. **(C)** Functional enrichment analyses of gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). **(D)** Univariate Cox regression analyses of the selected 154 genes in the training set based on the TCGA cohort, with $P < 0.05$ indicating statistical significance. **(E)** LASSO analysis identifying 5 survival-related genes. **(F)** Cross-validation for parameter selection in the LASSO regression. **(G)** Multivariate Cox regression analyses based on the univariate Cox regression analysis results. **(H)** Heat map of 5 differential genes in prognostic models, with red indicating high expression, blue indicating low expression.

low-risk group, the high-risk group had a higher mortality rate and shorter survival time. A high prognostic index score correlated with poor disease prognosis (Figure 3A–D). In the high-risk group, high expression of RMND5B, TRIM32 and UBE2L3, and low expression of RNF130 and HBP1 were observed (Figure 3E and F). The KM curve demonstrated a relatively poor prognosis in the high-risk group ($P < 0.05$, Figure 3G and H). Time-dependent ROC curve analysis showed the accuracy of OS prediction at 1, 3, and 5 years as follows: Training set: 0.75514 (95% CI 0.6697–0.8406), 0.75983 (95% CI 0.6663–0.8533), and 0.74496 (95% CI 0.6321–0.8578, Figure 3I), Test set: 0.65676 (95% CI 0.6106–0.7029), 0.5996 (95% CI 0.548–0.6512), and 0.59862 (95% CI 0.5436–0.6537, Figure 3J) respectively. These results suggested that the E3 ubiquitin ligase-associated features in our model may contribute to predicting the prognosis of AML with reliable accuracy.

Independent Prognostic Analysis of Risk Score and Clinical Features

To validate whether the risk score and clinical features could serve as independent prognostic factors, univariate and multivariate independent prognostic analyses were conducted. Univariate analyses revealed significant correlations between age, cytogenetic risk stratification, risk score, and OS in patients with AML. Multivariate independent prognostic analysis indicated that the risk score may be an independent predictive factor (Figure 3K and L).




Figure 3 Validation of prognostic models and independent prognosis analysis. (A) Patients in the training set are divided into two groups based on the median risk score. (B) Patients in the test set are divided into two groups based on the median risk score. (C) Survival status of high- and low-risk groups of patients with AML in training set. (D) Survival status of high- and low-risk groups of patients with AML in test set. (E) Heatmap showing the expression of five E3 ubiquitin ligase-related genes in training set. (F) Heatmap showing the expression of five E3 ubiquitin ligase-related genes in test set. (G) Kaplan-Meier curves showing the overall survival of high- and low-risk group patients in training set. (H) Kaplan-Meier curves showing the overall survival of high- and low-risk group patients in test set. (I) Validation of the predictive efficiency of the risk score through ROC curve analysis in training set. (J) Validation of the predictive efficiency of the risk score through ROC curve analysis in test set. (K) Univariate independent prognosis Cox regression analysis of risk score and indicated clinical characteristics. (L) Multivariate independent prognosis Cox regression analysis of risk score and indicated clinical characteristics.

Construction of Nomogram and Calibration Curves

A nomogram was created incorporating age, sex, white blood cell count, cytogenetic risk stratification, molecular mutation and risk scores (Figure 4A). The nomogram demonstrated the risk score as an important factor among various clinical parameters. Additionally, we constructed calibration curves that showed a close match between the nomogram and the actual survival rates of patients with AML (Figure 4B–D). The decision curve analysis (DCA) and ROC curves showed a significant advantage of the risk model in predicting survival time in the training cohort (Figure 4E–H).




Figure 4 Nomogram to predict the survival probability of patients with AML. (A) Nomogram combining the risk score with AML prognostic factors such as cytogenetic risk stratification. (B-D) calibration plots for predicting the 1-, 2-, and 3-year overall survival of patients. (E) ROC curve for survival prediction using the risk score and other variables (age, gender, white blood cell count, cytogenetic risk stratification). (F-H) Decision curve analysis of the nomogram.

ROC Curve and Kaplan-Meier Plots of Prognostic Genes

Drawing ROC curves based on patient survival outcomes, we can find that UBE2L3 has better specificity and sensitivity for distinguishing the prognosis of AML patients than the other 4 genes in the model (Figure 5A-E). Kaplan-Meier plots were generated to assess the association between the expression of E3 ubiquitin ligase-related genes in the prognostic model and AML prognosis. The results revealed that patients with AML with high UBE2L3, RMND5B and TRIM32 expression exhibited a poorer prognosis ($P < 0.05$, Figure 5F-H), whereas those with high RNF130 and HBP1 expression showed a better prognosis ($P < 0.05$, Figure 5I and J).




Figure 5 Prediction of disease outcome and survival analysis by model genes. (A-E) The ROC curves of HBP1, RNF130, RMND5B, TRIM22, and UBE2L3 for predicting survival outcomes. (F-J) The survival curves of UBE2L3, RMND5B, TRIM32, RNF130, HBP1.




Figure 6 Validation of cell lines and clinical samples. **(A)** Relative expression levels of UBE2L3 mRNA in wild-type leukemia cell lines (K562-WT and HL60-WT) and Adriamycin-resistant cell lines (K562/ADR and HL60/ADR). **(B and C)** Relative expression levels of UBE2L3 protein in wild-type leukemia cell lines and Adriamycin-resistant cell lines. **(D)** Changes in UBE2L3 expression newly diagnosed and after relapse in 8 patients with AML. **(E)** The survival curves of UBE2L3 in 49 patients with AML. ** $P < 0.01$, *** $P < 0.001$.

UBE2L3 Is Expressed in Cell Lines and in Patients With AML

In the K562 and HL60 cell lines, UBE2L3 expression in the mRNA and protein levels of the drug-resistant cell lines was higher than that of the wild-type cell lines ($P < 0.05$, Figure 6A–C). Compared with patients with newly diagnosed AML, the expression of UBE2L3 mRNA in the bone marrow of relapsed and refractory patients was increased ($P < 0.05$, Figure 6D). Through the Kaplan-Meier plots, we also can find that high expression of UBE2L3 has a poor prognosis ($P < 0.05$, Figure 6E). The characteristics of the patients is presented in [Supplemental Table 1](#).

Discussion

AML is a highly heterogeneous hematologic malignancy with significant variations in pathology, molecular basis, clinical treatment, and response to therapy.²⁵ The role of E3 ubiquitin ligases in the ubiquitin-proteasome pathway has gathered increasing attention in research regarding tumor onset and progression.^{26–32}

In this study, an AML prognostic risk model was first constructed through a systematic analysis of E3 ubiquitin ligase-related genes. A risk model was then constructed and validated using univariate Cox regression and LASSO analyses. This model included five genes (HBP1, RNF130, RMND5B, TRIM32 and UBE2L3). Ultimately, HBP1 and RNF130 were identified as protective factors for the disease, whereas RMND5B, TRIM32 and UBE2L3 was determined to be a risk factor for AML drug resistance and prognosis. HMG box protein 1 (HBP1) is a transcription factor and a potent cell cycle inhibitor in normal and cancer cells.³³ HBP1 is ubiquitinated by the CTLH E3 ubiquitin ligase complex, leading to its degradation and thus preventing cell cycle exit in G1 phase.³⁴ As an

E3 ubiquitin ligase, RNF130 may be involved in programmed cell death, immune regulation, tumor progression, etc.^{34,35} As a core component of the CTLH E3 ubiquitin-protein ligase complex, RMND5B selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1.³⁶ TRIM32 is a member of the tripartite motif family, which mediates and regulates many physiological and pathophysiological processes such as cell growth, immunity, carcinogenesis, etc. through its E3 ubiquitin ligase activity.³⁷ UBE2L3 is one of the many E2 ubiquitin conjugating enzymes, it plays a biological role in conjunction mainly with HECT or RBR (RING-in- Between-RING) E3.²³ In recent years, more and more studies have shown that UBE2L3 is significantly related to the occurrence and development of tumor, involving multiple signaling pathways, such as NF- κ B signaling pathway, GSK3 β /p65 signaling pathway, p53 signaling pathway, DSB repair pathways.^{20,38–40}

Drug resistance affects the chemotherapy effect of AML patients, thereby affecting the prognosis. The drug resistance mechanism of cells mainly includes the following aspects: first, the impact of cell membrane transport proteins on the uptake of water-soluble drugs; second, changes in the cell cycle, increased repair of DNA damage, reduced cell apoptosis, and changes in drug metabolism, which affects the killing of cells by cytotoxic drugs; finally, energy-dependent efflux of hydrophobic drugs is increased.⁴¹ Sang Ah Yi et al found that in the DNA damage response induced by doxorubicin, nuclear translocation of HP1 γ and binding on the UBE2L3 promoter mediate UBE2L3 silencing and increase p53 stability, which improves chemosensitivity in cisplatin-resistant cervical cancer.^{21,39} Depletion of UBE2L3 stabilizes 53BP1, sensitizing cells to DNA damage and further enhancing the effects of radiotherapy or chemotherapy.⁴⁰ However, when UBE2L3 is overexpressed, the multifunctional protein p27 is stabilized and promotes cell migration.⁴² The study demonstrated that overexpression of UBE2L3 significantly activated the nuclear factor kappa B (NF- κ B) signaling pathway through promoting NF- κ B p65 nuclear translocation and the ubiquitination and degradation of I κ B α protein that can head and neck squamous cell carcinoma progression.³⁸ UBE2L3 interacts with various E3 ubiquitin ligases to regulate the NF- κ B signaling pathway. In response to IL-1R stimulation, TAX binds to UBE2L3, thereby regulating the degradation and activation of NF- κ B.⁴³ In the TNFR pathway, UBE2L3 binds to LUBAC to initiate the synthesis of linear ubiquitin chains, which ultimately activate NF- κ B.⁴⁴ In addition, E6AP can interact with UBE2L3 to promote the ubiquitination and degradation of p53.⁴⁵ Increasing evidence shows that UBE2L3 plays an important role in the occurrence, development, and invasion of tumor.^{21,27,38,46} However, most of these studies have been conducted in solid tumors, and research on UBE2L3 in AML remains absent.

In addition, we further confirmed through leukemia cell lines and clinical samples that the relative expression of UBE2L3 in drug-resistant cell lines was significantly increased compared with wild type. In clinical samples, the expression of UBE2L3 in relapsed and refractory patients was significantly higher than that in newly diagnosed patients. However, our study has some limitations, including the lack of large-scale clinical cohort studies to validate the predictive efficacy and broad applicability of our model. In subsequent studies, we plan to increase the sample size and include more case samples to further explore the role of UBE2L3 in drug resistance, relapse, and refractory AML patients.

Conclusion

In this study, we developed a gene prognostic model based on HBP1, RNF130, RMND5B, TRIM32, and UBE2L3 to effectively predict the prognosis of AML patients. In addition, *in vitro* cell experiment results and clinical sample studies have shown that high expression of UBE2L3 is a reliable biomarker for drug resistance and poor prognosis of acute myeloid leukemia.

Data Sharing Statement

Public data were download from The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov>, project: TCGA-LAML), Beat AML 2.0 data (www.vizome.org). E3 ubiquitin ligase-related genes are from <https://www.geneCards.org> and <https://www.uniprot.org>.

Ethics Statement

The study protocol was approved by the Ethics Committee of Affiliated Chuzhou Hospital of Anhui Medical University, First People's Hospital of Chuzhou (approval number: 2024005). The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. All patients provided written informed consent. The use of cell lines was confirmed to have received approval from the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (approval number: 2024-031).

Acknowledgments

K562/ADR and HL60/ADR cell lines were donated by Professor Zhao Li from the Central Laboratory of the First Hospital of Lanzhou University.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work was supported by Health Research Program of Anhui, AHWJ2023BAa20051.

Disclosure

The authors declare no competing interest related to this study.

References

1. Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. *J Hematol Oncol.* 2020;13(1):72. doi:10.1186/s13045-020-00908-z
2. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. *Nature.* 2018;562(7728):526–531. doi:10.1038/s41586-018-0623-z
3. Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. *Drug Resist Updat.* 2020;48:100663. doi:10.1016/j.drup.2019.100663
4. Ortiz-Lazareno PC, Bravo-Cuellar A, Lerma-Díaz JM, et al. Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss. *Cancer Cell Int.* 2014;14(1):13. doi:10.1186/1475-2867-14-13
5. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. *Nat Med.* 2014;20(11):1242–1253. doi:10.1038/nm.3739
6. Hanzl A, Barone E, Bauer S, et al. E3-specific degrader discovery by dynamic tracing of substrate receptor abundance. *J Am Chem Soc.* 2023;145(2):1176–1184. doi:10.1021/jacs.2c10784
7. Xu H, Hu R, Zhao Z. DegronMD: leveraging evolutionary and structural features for deciphering protein-targeted degradation, mutations, and drug response to degrons. *Mol Biol Evol.* 2023;40(12). doi:10.1093/molbev/msad253
8. Yang L, Chen J, Huang X, Zhang E, He J, Cai Z. Novel insights into E3 ubiquitin ligase in cancer chemoresistance. *Am J Med Sci.* 2018;355(4):368–376. doi:10.1016/j.amjms.2017.12.012
9. Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. *Nat Struct mol Biol.* 2014;21(4):301–307. doi:10.1038/nsmb.2780
10. David Y, Ternette N, Edelmann MJ, et al. E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes. *J Biol Chem.* 2011;286(51):44104–44115. doi:10.1074/jbc.M111.234559
11. Drula R, Iluta S, Gulei D, et al. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. *Blood Rev.* 2022;56:100971. doi:10.1016/j.blre.2022.100971
12. Park IK, Blum W, Baker SD, Caligiuri MA. E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. *Leukemia.* 2017;31(2):502–505. doi:10.1038/leu.2016.293
13. Wang H, Bei L, Shah CA, Huang W, Plataniias LC, Eklund EA. The E3 ubiquitin ligase Triad1 influences development of MLL-Ell-induced acute myeloid leukemia. *Oncogene.* 2018;37(19):2532–2544. doi:10.1038/s41388-018-0131-5
14. Sanarico AG, Ronchini C, Croce A, et al. The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. *Leukemia.* 2018;32(4):911–919. doi:10.1038/leu.2017.342
15. Khateb A, Deshpande A, Feng Y, et al. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. *Nat Commun.* 2021;12(1):5397. doi:10.1038/s41467-021-25664-7
16. Wang L, Zhao S, Wang Y, Liu J, Wang X. UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation. *BMC Cancer.* 2024;24(1):497. doi:10.1186/s12885-024-12212-x

17. DiNardo CD, Olin R, Wang ES, et al. Phase I dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. *Cancer Med.* 2024;13(14):e70028. doi:10.1002/cam4.70028
18. Hansen JD, Correa M, Alexander M, et al. CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia. *J Med Chem.* 2021;64(4):1835–1843. doi:10.1021/acs.jmedchem.0c01489
19. He ZX, Yang WG, Zengyangzong D, et al. Targeting cullin neddylation for cancer and fibrotic diseases. *Theranostics.* 2023;13(14):5017–5056. doi:10.7150/thno.78876
20. Tao NN, Zhang ZZ, Ren JH, et al. Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3 β /p65 pathway. *Cancer Lett.* 2020;481:1–14. doi:10.1016/j.canlet.2020.03.028
21. Yi SA, Lee DH, Kim GW, et al. HPV-mediated nuclear export of HP1 γ drives cervical tumorigenesis by downregulation of p53. *Cell Death Differ.* 2020;27(9):2537–2551. doi:10.1038/s41418-020-0520-5
22. Wang XS, Shankar S, Dhanasekaran SM, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. *Cancer Discov.* 2011;1(1):35–43. doi:10.1158/2159-8274.Cd-10-0022
23. Zhang X, Huo C, Liu Y, Su R, Zhao Y, Li Y. Mechanism and disease association with a ubiquitin conjugating E2 enzyme: UBE2L3. *Front Immunol.* 2022;13:793610. doi:10.3389/fimmu.2022.793610
24. Lu J, Dong Q, Zhang S, Feng Y, Yang J, Zhao L. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling. *Cancer Sci.* 2023;114(8):3287–3300. doi:10.1111/cas.15855
25. Xu L, Zhang Y, Qu X, et al. E3 ubiquitin ligase Cbl-b prevents tumor metastasis by maintaining the epithelial phenotype in multiple drug-resistant gastric and breast cancer cells. *Neoplasia.* 2017;19(4):374–382. doi:10.1016/j.neo.2017.01.011
26. Barrio S, Munawar U, Zhu YX, et al. IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. *Haematologica.* 2020;105(5):e237–e241. doi:10.3324/haematol.2019.217943
27. Gu C, Lu T, Wang W, et al. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. *Leukemia.* 2021;35(6):1803–1807. doi:10.1038/s41375-020-01033-z
28. Huang X, Gu H, Zhang E, et al. The NEDD4-1 E3 ubiquitin ligase: a potential molecular target for bortezomib sensitivity in multiple myeloma. *Int J Cancer.* 2020;146(7):1963–1978. doi:10.1002/ijc.32615
29. Kwanten B, Deconick T, Walker C, Wang F, Landesman Y, Daelemans D. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. *Biomed Pharmacother.* 2023;160:114305. doi:10.1016/j.biopha.2023.114305
30. Liu M, Aneja R, Wang H, et al. Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue 1. *J Pathol.* 2008;214(4):508–514. doi:10.1002/path.2312
31. Zhang G, Zhu Q, Yan X, et al. HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC. *Cell Death Discov.* 2022;8(1):185. doi:10.1038/s41420-022-01001-9
32. Zhu J, Li X, Su P, Xue M, Zang Y, Ding Y. The ubiquitin ligase RNF181 stabilizes ER α and modulates breast cancer progression. *Oncogene.* 2020;39(44):6776–6788. doi:10.1038/s41388-020-01464-z
33. Bollaert E, de Rocca Serra A, Demoulin JB. The HMG box transcription factor HBP1: a cell cycle inhibitor at the crossroads of cancer signaling pathways. *Cell mol Life Sci.* 2019;76(8):1529–1539. doi:10.1007/s00018-019-03012-9
34. Lampert F, Stafa D, Goga A, et al. The multi-subunit GID/CTLH E3 ubiquitin ligase promotes cell proliferation and targets the transcription factor Hbp1 for degradation. *Elife.* 2018;7. doi:10.7554/eLife.35528
35. Guais A, Siegrist S, Solhonne B, Jouault H, Guellaën G, Bulle F. h-Goliath, paralog of GRAIL, is a new E3 ligase protein, expressed in human leukocytes. *Gene.* 2006;374:112–120. doi:10.1016/j.gene.2006.01.028
36. Zhang J, Chen W, Du J, et al. RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination. *Int Immunopharmacol.* 2023;117:109985. doi:10.1016/j.intimp.2023.109985
37. Jeong SY, Choi JH, Kim J, Woo JS, Lee EH. Tripartite motif-containing protein 32 (TRIM32): what does it do for skeletal muscle? *Cells.* 2023;12(16):2104. doi:10.3390/cells12162104
38. Cui Z, Sun S, Li J, et al. UBE2L3 promotes squamous cell carcinoma progression in the oral cavity and hypopharynx via activating the NF- κ B signaling by increasing I κ B α degradation. *Cell Biol Int.* 2022;46(5):806–818. doi:10.1002/cbin.11772
39. Yi SA, Kim GW, Yoo J, Han JW, Kwon SH. HP1 γ sensitizes cervical cancer cells to cisplatin through the suppression of UBE2L3. *Int J mol Sci.* 2020;21(17):5976. doi:10.3390/ijms21175976
40. Han X, Zhang L, Chung J, et al. UbcH7 regulates 53BP1 stability and DSB repair. *Proc Natl Acad Sci U S A.* 2014;111(49):17456–17461. doi:10.1073/pnas.1408538111
41. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov.* 2006;5(3):219–234. doi:10.1038/nrd1984
42. Weinberg J, Whitcomb E, Bohm A, Chekilla UK, Taylor A. The E3 ligase SMURF1 stabilizes p27 via UbcH7 catalyzed K29-linked ubiquitin chains to promote cell migration SMURF1-UbcH7 K29 ubiquitination of p27 and cell migration. *J Biol Chem.* 2024;300(3):105693. doi:10.1016/j.jbc.2024.105693
43. Wang C, Long W, Peng C, et al. HTLV-1 tax functions as a ubiquitin E3 ligase for direct IKK activation via synthesis of mixed-linkage polyubiquitin chains. *PLoS Pathog.* 2016;12(4):e1005584. doi:10.1371/journal.ppat.1005584
44. Fu B, Li S, Wang L, Berman MA, Dorf ME. The ubiquitin conjugating enzyme UBE2L3 regulates TNF α -induced linear ubiquitination. *Cell Res.* 2014;24(3):376–379. doi:10.1038/cr.2013.133
45. Ciechanover A, Shkedy D, Oren M, Bercovich B. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. *J Biol Chem.* 1994;269(13):9582–9589. doi:10.1016/S0021-9258(17)36921-1
46. Liu Y, Song C, Ni H, et al. UBE2L3, a susceptibility gene that plays oncogenic role in hepatitis B-related hepatocellular carcinoma. *J Viral Hepat.* 2018;25(11):1363–1371. doi:10.1111/jvh.12963

International Journal of General Medicine

Dovepress

Taylor & Francis Group

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>